approach involving coccygectomy, a technique that has not previously been reported.
best possible course for somebody who has had the outline of a textbook accepted by a publisher is to join the Society of Authors. Members of the Society have access to staff who are expert in all aspects of contract, copyright and publishing, and their advice is free and independent. I am not suggesting that all publishers try to do authors down, but it is better to be on the safe side. This will protect both author and publisher. In addition to these valuable services the Medical Writers Group of the Society exists to promote good fellowship between medical writers. It organizes meetings, and also awards prizes for several categories of medical textbook one of which, the Asher Prize, is for the best ®rst book. These prizes are being supported this year by the Royal Society of Medicine.
Mary Evans
Chairman, Medical Writers Group, Society of Authors, 84 Drayton Gardens, London SW10 9SB, UK I was particularly interested by Dr Gordon's very acute Personal Paper because I was responsible for the RSM publications in the days when the Society used to work with a publishing partner.
While agreeing with almost all the advice he gives, I want to add one perception of my own. To my mind perhaps the most important discussion between would-be author and potential publisher is to make sure that both parties are on the same wavelength over whom the book is intended for. Is it for beginning students, graduate students, fellow clinicians or likely to be bought by libraries only? There is nothing inappropriate about discussing the competition and what the price will have to be if your book is to be bought. The price is often crucial.
I would strongly advise all authors to make sure they have a clear idea of the level for which they are writing and make sure that the publisher is in accord. It is not unreasonable to ask for an addendum to the contract setting out the agreed position. Editors come and go and publishing houses are bought and sold; something ®rm on paper will make sure that, even if the worst is threatened, the author can withdraw the ®nished manuscript and offer it elsewhere.
Anthony Watkinson
14 Park Street, Bladon, Woodstock, Oxon OX20 1RW, UK
It is appropriate that you should have published advice from a surgeon in North America. I have submitted two proposals in past years to different publishers for a book on the early management of spinal and spinal cord injury. There certainly is a gap on the shelves which this book would ®ll. After initial encouragement, which resulted in considerable preparatory work on my part, both proposals were rejected. The reasons given were similar:
I am not con®dent that we could sell such a book successfully, particularly in North America. As I am sure you understand, we do depend heavily on this market for sales of our more specialised books.' (Churchill Livingstone, 1986) Our sales and marketing staff did not feel that there would be suf®cient interest in the book outside the UK and this would restrict the print run to an uneconomical level.' (Butterworth Heinemann, 1992) Sadly it seems that British medical practice must be dictated by the North American market, and therefore by medical practice in North America, this despite the facts that both patient expectations and responses to diseases and their treatment, and the economics of medical practice, differ greatly in that continent from those in the British Isles.
R G Pringle
Burnell House, 82 Berwick Road, Shrewsbury SY1 2NF, UK Dr Gordon provides an excellent summary of the practical issues facing those who set out to write a book. The subject will have a further airing at the RSM's Millennium Members Day on 7 July, when I am to give a short talk on how to get a book published. I hope that existing authors will join us to share their experience and advice.
Peter Richardson
Director of Publications, The Royal Society of Medicine, London W1M 8AE, UK
Antithrombotic therapy in atrial ®brillation
Dr Adhiyaman and colleagues report underutilization of antithrombotic therapy in atrial ®brillation (March 2000 JRSM, pp 138±40). Adjusted-dose warfarin reduces risk for stroke by about 60% compared with placebo, aspirin reduces the risk (primarily for noncardioembolic ischaemic strokes which are less disabling than cardioembolic ischaemic strokes in atrial ®brillation) by about 20% compared with placebo, and warfarin reduces the risk by about 40% compared with aspirin 1 . Contrary to conventional wisdom, elderly patients with paroxysmal (41 episode) atrial ®brillation seem to have a risk for stroke similar to that of patients with sustained (persistent/ permanent) atrial ®brillation 1 .
Our hospital participated in the National Sentinel Clinical Audit of Evidence Based Prescribing for Older People conducted by the Royal College of Physicians, London. One arm of the audit was to assess use of 
